Dihydroartemisinin exerts cytotoxic effects and inhibits hypoxia inducible factor-1α activation in C6 glioma cells
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Artemisinin and its analogue dihydroartemisinin exert cytotoxic effects in some kinds of cancer cell lines. Here we determined whether dihydroartemisinin inhibits the growth and induces apoptosis of rat C6 glioma cells. We found dihydroartemisinin (5–25 μM) inhibited the growth and induced apoptosis of C6 cells in a concentration- and time-dependent manner; however, it was much less toxic to rat primary astrocytes. Dihydroartemisinin (5–25 μM) also increased the generation of reactive oxygen species in C6 cells. These effects of dihydroartemisinin were enhanced by ferrous ions (12.5–100 μM) and reduced by the iron chelator deferoxamine (25–200 μM). Immunoblotting analysis revealed that dihydroartemisinin (5–25 μM) significantly reduced hypoxia- and deferoxamine-induced expression of hypoxia inducible factor-1α and its target gene protein, vascular endothelial growth factor, in C6 cells. The results showed that dihydroartemisinin exerts a selective cytotoxic effect on C6 cells by increasing the reactive oxygen species and inhibiting hypoxia inducible factor-1α activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular and developmental control of O 2 homeostasis by hypoxia-inducible factor 1α
Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H., Gassmann, M., Gearhart, J. D., Lawler, A. M., Yu, A. Y., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.149 · Cited by 2,476 · cited 1×
“Under hypoxic conditions, HIF-1a is stabilized, translocated into the nucleus where it interacts with the hypoxia responsive elements, and then activates the target genes; however, it decreases rapidly under normoxia (Iyer et al 1998).”
BackgroundGeneral involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia.
Wang, G. L., & Semenza, G. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.9.4304 · Cited by 1,468 · cited 1×
“HIF-1a induces the expression of target proteins, including erythropoietin and VEGF, which are involved in cancer cell survival, migration, invasion and angiogenesis (Wang & Semenza 1993; Damert et al 1997).”
BackgroundMaxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Stratford, I. J., Hankinson, O., Pugh, C. W., & Ratcliffe, P. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.8104 · Cited by 1,084
Jensen, R. L., Ragel, B. T., Whang, K., & Gillespie, D. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-9103-z · Cited by 167
Cited by
From ancient herb to modern drug: Artemisia annua and artemisinin for cancer therapy
Efferth, T. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.02.009 · Cited by 632
Artemisinins: Pharmacological actions beyond anti-malarial
Ho, W. E., Peh, H. Y., Chan, T. K., & Wong, W. S. F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.001 · Cited by 481
Redox-Directed Cancer Therapeutics: Molecular Mechanisms and Opportunities
Wondrak, G. T. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2541 · Cited by 462
Crespo-Ortiz, M. P., & Wei, M. Q. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/247597 · Cited by 382
Hou, J., Wang, D., Zhang, R., & Wang, H. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0197 · Cited by 320
Metadata
- Authors
- Huang, X.-J., Ma, Z.-Q., Zhang, W.-P., Lu, Y.-B., & Wei, E.-Q.
- Venue
- Journal of Pharmacy and Pharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-06-01
- Volume
- 59
- Issue
- 6
- Pages
- 849-856
- ISSN
- 0022-3573 (ISSN-L)
- 2042-7158
- OpenAlex
- W2024217069
- Cited by
- 66
- References
- 4
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.